Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14701086 | 0.72 | MEN1 (0.46) | MAPK1AHRTSHRHSD17B10CYP3A4 | |
| SCHEMBL15188822 | 0.72 | CYP3A4 (0.46) | MAPK1HPGDTSHRHSD17B10CYP3A4 | |
| SCHEMBL14702123 | 0.69 | AHR (0.38) | MAPK1AHRHPGDTSHRHSD17B10 | |
| SCHEMBL1457091 | 0.69 | TDP1 (0.35) | MAPK1AHRHPGDTSHRHSD17B10 | |
| SCHEMBL30673507 | 0.69 | TDP1 (0.35) | MAPK1AHRHPGDTSHRHSD17B10 | |
| SCHEMBL1457032 | 0.69 | TDP1 (0.56) | MAPK1AHRHPGDTSHRHSD17B10 | |
| SCHEMBL348913 | 0.67 | AHR (0.67) | MAPK1AHRHPGDTSHRHSD17B10 | |
| SCHEMBL11794556 | 0.66 | MAPT (0.56) | MAPK1TSHRCYP3A4 | |
| SCHEMBL11882310 | 0.63 | HTR3E (0.52) | HPGDTSHRHSD17B10 | |
| SCHEMBL28697702 | 0.63 | MAPK1 (0.33) | MAPK1AHRHPGDTSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170121285-A1 | Selective androgen receptor modulators | RADIUS HEALTH INC (US) | 2017-05-04 | — | — | US | disclosed |
| US-20150266821-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | RADIUS HEALTH INC (US) | 2015-09-24 | — | — | US | disclosed |
| US-8987319-B2 | Selective androgen receptor modulators | RADIUS HEALTH, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130041007-A1 | Selective Androgen Receptor Modulators | RADIUS HEALTH, INC. | 2013-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121285-A1 | Selective androgen receptor modulators | AR, SHBG, FSHR | MAPK1 1483/4885AHR 304/4885HPGD 443/4885 |
| US-20150266821-A1 | SELECTIVE ANDROGEN RECEPTOR MODULATORS | AR, SHBG, FSHR | MAPK1 1471/4885AHR 303/4885HPGD 461/4885 |
| US-20130041007-A1 | Selective Androgen Receptor Modulators | AR, SHBG, GPR119 | MAPK1 1874/4885AHR 290/4885HPGD 777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.